Prosecution Insights
Last updated: July 17, 2026
Application No. 18/557,918

NOVEL TRIAZOLE-PYRIDINE SUBSTITUTED PYRROLIDINYL AND TETRAHYDRO-2H-PYRANYL ACETIC ACID COMPOUNDS AS LPA ANTAGONISTS

Non-Final OA §112
Filed
Oct 27, 2023
Priority
Apr 30, 2021 — WO PCT/CN2021/091510 +1 more
Examiner
KENYON, JOHN S
Art Unit
1625
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Viva Star Biosciences (Suzhou) Co. Ltd.
OA Round
1 (Non-Final)
80%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
98%
With Interview

Examiner Intelligence

Grants 80% — above average
80%
Career Allowance Rate
755 granted / 941 resolved
+20.2% vs TC avg
Strong +18% interview lift
Without
With
+17.5%
Interview Lift
resolved cases with interview
Typical timeline
2y 4m
Avg Prosecution
48 currently pending
Career history
984
Total Applications
across all art units

Statute-Specific Performance

§101
1.8%
-38.2% vs TC avg
§103
20.0%
-20.0% vs TC avg
§102
25.9%
-14.1% vs TC avg
§112
30.3%
-9.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 941 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. Election/Restrictions Applicant’s election without traverse in the reply filed on 26 February 2026, is acknowledged. Applicants’ provided a compliant species election to: PNG media_image1.png 326 318 media_image1.png Greyscale (CAS RN: 2858646-52-1), which is a species of genus formula I of instant claim 1, wherein: “A” is a 5-membered heterocyclyl of formula: PNG media_image2.png 124 196 media_image2.png Greyscale ; L1 is a covalent bond; L2 is (CR7R7)p; L3 is O; Q is a 6-membered heteroaryl group substituted with (R3)n and one R4; X1 is N; X2 is N; X3 is NR6 wherein dashed circle denotes bonds forming a 5-membered aromatic ring; Y1 is CR5 wherein R5 is methyl; Y2 is N; Y3 and Y4 are each independently CR5 wherein R5 at each occurrence is independently hydrogen (H); R2 at each occurrence is H; R4 is C4cycloalkyl; R6 is methyl; R7 at each occurrence is H; m is 0; n is 0; and p is 1. The elected species is free of the prior art. The Examiner extended the Markush search to any compounds wherein ring A is A1, but did not retrieve prior art. See “SEARCH 6” in enclosed search notes. The Examiner extended the Markush search to the full scope of instant claims 1 and 69 but did not retrieve any prior art. Therefore, the Election of Species Requirement of 7 January 2026, is withdrawn, as all claims are free of the prior art. All claims have been examined on the merits. Current Status of 18/557,918 This Office Action is responsive to the amended claims of 26 February 2026. Claims 1-2, 9, 13, 15, 18, 21-22, 25-26, 29, 32, 35-36, 39, 42, 45-46, 49-50, 54, 57, 60-61, 64-65, and 68-74 have been examined on the merits. Claims 2, 60, 68, and 70-71 are original. Claims 1, 50, 64, 69, and 74 are currently amended. Claims 9, 13, 15, 18, 21-22, 25-26, 29 32, 35-36, 39, 42, 45-46, 49, 54, 57, 61, 65, and 72-73 are previously presented. Priority The effective filing date is 30 April 2021. Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55. Information Disclosure Statement The information disclosure statement (IDS) submitted on 27 October 2023, is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner. Specification The title of the invention contains “Novel”. The title of the invention is not descriptive. The words “New”, “Novel”, “Improvement” are not permitted in the title. See MPEP 606 for a list of all prohibited words. A new title is required that is clearly indicative of the invention to which the claims are directed. The following title is suggested: -- [[NOVEL]] TRIAZOLE-PYRIDINE SUBSTITUTED PYRROLIDINYL AND TETRAHYDRO-2H-PYRANYL ACETIC ACID COMPOUNDS AS LPA ANTAGONISTS -- . Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 74 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. The claim 74 contains both: 1) “e.g.” and 2) limitations within parentheticals. The abbreviation “e.g.” which is interpreted as “for example” renders the metes and bounds of claim 74 undefined (hence rendering claim 74 indefinite under 35 USC 112(b)): the artisan does not know if the limitations following “e.g.” are merely exemplary or are required limitations of the claim. Please delete “e.g.” to render moot this portion of the rejection. Separately, the limitations within parentheticals render the metes and bounds of claim 74 undefined (hence rendering claim 74 indefinite under 35 USC 112(b)): the artisan does not know if the limitations within the parentheticals are merely exemplary or are required limitations of the claim. The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claim 9 is rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Dependent claim 9, drawn to “L1 being one of covalent bond, NH, O, or S” does not further limit the identically same choices presented in parent claim 1. Therefore, claim 9 is rejected under 35 USC 112(d). Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Conclusion Claims 9 and 74 are not presently allowable as written. Claims 1-2, 13, 15, 18, 21-22, 25-26, 29, 32, 35-36, 39, 42, 45-46, 49-50, 54, 57, 60-61, 64-65, and 68-73 are presently allowable as written. The elected species is free of the prior art. This search (see enclosed search notes) is governed by the disclaimer for variable L1 according to instant claim 1. A search for the genus form encompassing the elected species: PNG media_image3.png 450 338 media_image3.png Greyscale , wherein Ring A is A1, and wherein R1 is Nitrogen (N) or carbon (C); and R2 is N, O, S, or C, did not retrieve any prior art. See “SEARCH 6” in enclosed search notes. This search (see enclosed search notes) is governed by the disclaimer for variable L1 according to instant claim 1. A search for the genus form encompassing the Markush search extension wherein Ring A is A2: PNG media_image4.png 464 234 media_image4.png Greyscale , and wherein R1 is Nitrogen (N) or carbon (C); and R2 is N, O, S, or C, did not retrieve any prior art. See “SEARCH 7” in enclosed search notes. This search (see enclosed search notes) is governed by the disclaimer for variable L1 according to instant claim 1. A search for the genus formula IV of instant claim 69 did not retrieve any prior art. See “SEARCH 8” in enclosed search notes. A search for the genus formula I of instant claim 1 wherein ring A is A3 did not retrieve any prior art. See “SEARCH 9” in enclosed search notes. This search (see enclosed search notes) is governed by the disclaimer for variable L1 according to instant claim 1. A search for the genus formula I of instant claim 1 wherein ring A is A4 did not retrieve any prior art. See “SEARCH 10” in enclosed search notes. This search (see enclosed search notes) is governed by the disclaimer for variable L1 according to instant claim 1. A search for the genus formula I of instant claim 1 wherein ring A is A5 did not retrieve any prior art. See “SEARCH 11” in enclosed search notes. This search (see enclosed search notes) is governed by the disclaimer for variable L1 according to instant claim 1. A search for the genus formula I of instant claim 1 wherein ring A is A6 did not retrieve any prior art. See “SEARCH 12” in enclosed search notes. This search (see enclosed search notes) is governed by the disclaimer for variable L1 according to instant claim 1. A search for the genus formula I of instant claim 1 wherein ring A is A7 did not retrieve any prior art. See “SEARCH 13” in enclosed search notes. This search (see enclosed search notes) is governed by the disclaimer for variable L1 according to instant claim 1. The reference CHENG (WO 2020/060915 A1, provided by Applicants and referenced in IDS of 27 October 2023) discloses compound 11: PNG media_image5.png 264 352 media_image5.png Greyscale (on page 137). However, it is structurally distinct from the instant claim 1 at least in two ways: (1) it does not follow the disclaimer for Y1-Y4 requiring that “at least one but no more than two of Y1, Y2, Y3, and Y4 are N”; and (2) it does not conform to the disclaimers of variable L1 and (3) does not have a ring “A” structurally the same as any of A1-A7. These constitute two or more structural differences too many to make a viable obviousness rejection without running afoul of hindsight reasoning. Furthermore, the reference WO 2019/126084, which is referenced in IDS of 27 October 2023, discloses the compound: PNG media_image6.png 252 578 media_image6.png Greyscale (page 91). However, it is structurally distinct from the instant claim 1 as it does not follow the disclaimer for Y1-Y4 requiring that “at least one but no more than two of Y1, Y2, Y3, and Y4 are N”. It would not be obvious to randomly place a nitrogen on one or two of the positions Y1-Y4 to attempt to arrive at the instant invention. Any inquiry concerning this communication or earlier communications from the examiner should be directed to JOHN S KENYON whose telephone number is (571)270-1567. The examiner can normally be reached Monday-Friday 10a-6p. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Andrew D Kosar can be reached at (571) 272-0913. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JOHN S KENYON/Primary Patent Examiner, Art Unit 1625
Read full office action

Prosecution Timeline

Oct 27, 2023
Application Filed
Jun 08, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12678472
METHOD FOR SELECTIVE RECOVERY OF HYDROPHOBIC COMPOUNDS
4y 2m to grant Granted Jul 14, 2026
Patent 12679819
METHOD OF PREPARING ORGANOSULFUR COMPOUND
3y 2m to grant Granted Jul 14, 2026
Patent 12679824
NOVEL IMIDAZOLE-PYRAZOLE DERIVATIVES
3y 4m to grant Granted Jul 14, 2026
Patent 12677847
METHODS AND FORMULATIONS FOR REDUCING BOVINE EMISSIONS
2y 7m to grant Granted Jul 14, 2026
Patent 12655132
CRYSTAL FORMS OF A PYRIDAZINONE TRPC INHIBITOR
4y 8m to grant Granted Jun 16, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
80%
Grant Probability
98%
With Interview (+17.5%)
2y 4m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 941 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month